[go: up one dir, main page]

NO975309D0 - Anvendelse av rivavirin og alfa-interferon til behandling av hepatitt C - Google Patents

Anvendelse av rivavirin og alfa-interferon til behandling av hepatitt C

Info

Publication number
NO975309D0
NO975309D0 NO975309A NO975309A NO975309D0 NO 975309 D0 NO975309 D0 NO 975309D0 NO 975309 A NO975309 A NO 975309A NO 975309 A NO975309 A NO 975309A NO 975309 D0 NO975309 D0 NO 975309D0
Authority
NO
Norway
Prior art keywords
rivavirin
hepatitis
treatment
alpha interferon
interferon
Prior art date
Application number
NO975309A
Other languages
English (en)
Norwegian (no)
Other versions
NO975309L (no
Inventor
Janice K Albrecht
Paul C Grint
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of NO975309L publication Critical patent/NO975309L/no
Publication of NO975309D0 publication Critical patent/NO975309D0/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO975309A 1995-05-19 1997-11-19 Anvendelse av rivavirin og alfa-interferon til behandling av hepatitt C NO975309D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/444,584 US6387365B1 (en) 1995-05-19 1995-05-19 Combination therapy for chronic hepatitis C infection
PCT/US1996/006552 WO1996036351A1 (en) 1995-05-19 1996-05-15 Use of ribavirin and interferon alpha for the treatment of hepatitis c

Publications (2)

Publication Number Publication Date
NO975309L NO975309L (no) 1997-11-19
NO975309D0 true NO975309D0 (no) 1997-11-19

Family

ID=23765515

Family Applications (1)

Application Number Title Priority Date Filing Date
NO975309A NO975309D0 (no) 1995-05-19 1997-11-19 Anvendelse av rivavirin og alfa-interferon til behandling av hepatitt C

Country Status (15)

Country Link
US (2) US6387365B1 (pt)
EP (2) EP1005868A1 (pt)
JP (1) JPH10506640A (pt)
KR (1) KR19990014925A (pt)
CN (1) CN1190895A (pt)
AU (1) AU5919296A (pt)
BR (1) BR9608758A (pt)
CA (1) CA2221314A1 (pt)
CZ (1) CZ365497A3 (pt)
HU (1) HUP9802324A3 (pt)
NO (1) NO975309D0 (pt)
NZ (1) NZ309217A (pt)
PL (1) PL323477A1 (pt)
SK (1) SK155997A3 (pt)
WO (1) WO1996036351A1 (pt)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2686899B1 (fr) * 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
JP2000507917A (ja) * 1995-11-02 2000-06-27 シェーリング コーポレイション 持続的低用量サイトカイン注入治療
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
SK283342B6 (sk) * 1996-01-23 2003-06-03 Icn Pharmaceuticals Použitie ribavirínu na prípravu farmaceutického prostriedku
JP3416147B2 (ja) * 1996-01-23 2003-06-16 アイ・シー・エヌ・フアーマシユーテイカルズ・インコーポレイテツド 活性化ｔリンパ球におけるリバビリン及びリバビリン類似体によるｔｈ１型／ｔｈ２型サイトカインの発現の調節
US20020137696A1 (en) * 1996-01-23 2002-09-26 Robert Tam Specific modulation of TH1/TH2 cytokine expression by ribavirin in activated T-lymphocytes
BR9707772A (pt) * 1996-02-28 2000-01-04 Ifi Istituto Farmacoterapico I Composições farmacêuticas compreendendo alfa-interferon humano natural
AU5157998A (en) * 1996-11-01 1998-05-29 Thomas Najarian Methods and compositions for treatment of hepatitis c infection
DE69810822T2 (de) * 1997-09-21 2003-11-20 Schering Corp., Kenilworth Kombinationstherapie zur Entfernung von nachweisbarer HCV-RNS in Patienten mit chronischer Hepatitis C-Infection
US6172046B1 (en) 1997-09-21 2001-01-09 Schering Corporation Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection
US6472373B1 (en) 1997-09-21 2002-10-29 Schering Corporation Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection
US6337090B1 (en) * 1997-12-22 2002-01-08 Schering Corporation Orally administrable solid ribavirin dosage forms and process for making them
ES2172288T3 (es) * 1998-05-15 2002-09-16 Schering Corp Terapia de combinacion que comprende ribavirina e interferon alfa en pacientes que no han sido sometidos a tratamiento antiviral y que tienen infeccion cronica de hepatitis c.
ID29285A (id) * 1998-06-08 2001-08-16 Hoffmann La Roche PENGGUNAAN PEG-IFN-α DAN RIBAVIRIN UNTUK PENGOBATAN HEPATITIS C KRONIS
WO2000013708A1 (en) * 1998-09-04 2000-03-16 Viropharma Incorporated Methods for treating or preventing viral infections and associated diseases
RU2001113268A (ru) * 1998-10-16 2003-09-27 Шеринг Корпорейшн (US) Сочетанная терапия рибавирином и интерфероном α для удаления определяемой рнк вируса гепатита с у пациентов с хроническим гепатитом с
US6277830B1 (en) 1998-10-16 2001-08-21 Schering Corporation 5′-amino acid esters of ribavirin and the use of same to treat hepatitis C with interferon
US6403564B1 (en) 1998-10-16 2002-06-11 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
EP1140143A2 (en) * 1998-12-18 2001-10-10 Schering Corporation Ribavirin-pegylated interferon alfa induction hcv combination therapy
US6824768B2 (en) * 1998-12-18 2004-11-30 Schering Corporation Ribavirin-pegylated interferon alfa induction HCV combination therapy
WO2000037097A1 (en) * 1998-12-18 2000-06-29 Schering Corporation Ribavirin-interferon alfa induction hcv combination therapy
WO2001077137A1 (en) * 2000-04-12 2001-10-18 Human Genome Sciences, Inc. Albumin fusion proteins
HK1049944A1 (zh) * 1999-12-23 2003-06-06 Icn Pharmaceuticals, Inc. L-核苷、l-核苷酸及其类似物的组合物和治疗方法
EP1282632A1 (en) * 2000-04-20 2003-02-12 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable hcv-rna in patients having chronic hepatitis c infection
YU7503A (sh) * 2000-08-02 2006-03-03 Ortho-Mcneil Pharmaceutical Inc. Anti-virusna i anti-tumorna hemoterapija poboljšana davanjem eritropoetina
US6946125B2 (en) * 2000-08-23 2005-09-20 The New York Hospital Medical Center Of Queens Methods of treating West Nile virus infection
US20060024270A1 (en) * 2000-08-23 2006-02-02 The New York Hospital Medical Center Of Queens Compositions and methods for preventing or treating encephalitis with interferon
BR0114636A (pt) * 2000-10-18 2004-02-10 Schering Corp Terapia combinada para hcv de interferon-alfa peguilado/ribavirina
US6720000B2 (en) 2001-03-19 2004-04-13 Three Rivers Pharmaceutical, Llc Process for producing wet ribavirin pellets
EP1401477A4 (en) * 2001-05-25 2005-02-02 Human Genome Sciences CHIMIOKINE BETA-1 HYBRID PROTEINS
JP2005517648A (ja) * 2001-12-07 2005-06-16 インターミューン インコーポレイテッド 肝炎ウイルス感染症を治療するための組成物および方法
KR101271635B1 (ko) * 2001-12-21 2013-06-12 휴먼 게놈 사이언시즈, 인코포레이티드 알부민 융합 단백질
EP2277889B1 (en) 2001-12-21 2014-07-09 Human Genome Sciences, Inc. Fusion proteins of albumin and interferon beta
EP1534299A4 (en) * 2002-07-02 2007-04-11 Corcept Therapeutics Inc METHOD FOR TREATING PSYCHOSIS IN CONNECTION WITH INTERFERON-ALPHA THERAPY
EP1539960B1 (en) * 2002-09-09 2010-04-28 Hanall Pharmaceutical Co., Ltd. Protease-resistant modified interferon alpha polypeptides
US7538094B2 (en) 2002-09-19 2009-05-26 Three Rivers Pharmacueticals, Llc Composition containing ribavirin and use thereof
JP2004143113A (ja) * 2002-10-25 2004-05-20 Shinya Nakajima インターフェロン製剤及びその投与システム
EP1594530A4 (en) 2003-01-22 2006-10-11 Human Genome Sciences Inc HYBRID PROTEINS OF ALBUMIN
GB0301879D0 (en) * 2003-01-27 2003-02-26 Regent Res Llp HCV combination therapy
CN1980678A (zh) * 2003-03-28 2007-06-13 法莫赛特股份有限公司 治疗黄病毒感染的化合物
NZ544789A (en) 2003-07-18 2010-01-29 Vertex Pharma Dithia-azaspiro-nonane and decane derivatives as inhibitors of serine proteases
JPWO2006033453A1 (ja) * 2004-09-22 2008-05-15 学校法人順天堂 インターフェロン作用物質の活性増強剤
US7723310B2 (en) 2004-10-18 2010-05-25 Three Rivers Pharmaceuticals, Llc Large dose ribavirin formulations
EP1850862A2 (en) * 2005-01-19 2007-11-07 Avigenics, Inc. Methods of treating disease with glycosylated interferon
WO2007013677A1 (ja) * 2005-07-27 2007-02-01 Ajinomoto Co., Inc. インターフェロン作用物質の活性増強剤
JP2009545621A (ja) 2006-08-02 2009-12-24 ユナイテッド セラピューティクス コーポレーション ウィルス感染症のリポソーム処置
US20080131398A1 (en) * 2006-08-21 2008-06-05 United Therapeutics Corporation Combination therapy for treatment of viral infections
US20080260820A1 (en) * 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
WO2009015336A2 (en) * 2007-07-25 2009-01-29 Biolex Therapeutics, Inc. Controlled release interferon drug products and treatment of hcv infection using same
CN102046151A (zh) * 2008-03-26 2011-05-04 牛津大学 靶向内质网的脂质体
KR20110054003A (ko) * 2008-09-17 2011-05-24 베링거 인겔하임 인터내셔날 게엠베하 Ｈｃｖ ｎｓ3 프로테아제 억제제와 인터페론 및 리바비린의 병용물
KR20120059447A (ko) * 2009-03-27 2012-06-08 더 챈슬러 마스터즈 앤드 스칼라스 오브 더 유니버시티 오브 옥스포드 콜레스테롤 수준 저하 리포좀
US20110027229A1 (en) 2009-07-31 2011-02-03 Medtronic, Inc. Continuous subcutaneous administration of interferon-alpha to hepatitis c infected patients
EA201200650A1 (ru) 2009-10-30 2012-12-28 Бёрингер Ингельхайм Интернациональ Гмбх Курсы комбинированного лечения вируса гепатита с, включающие bi201335, интерферон-альфа и рибавирин
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
CA2811250C (en) 2011-10-21 2015-08-11 Abbvie Inc. Methods for treating hcv
SE1450019A1 (sv) 2011-10-21 2014-01-10 Abbvie Inc Förfaranden för att behandla HCV innefattande minst två direktverkande antivirala agenser, ribavirin men inte interferon
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
EP2809334A4 (en) * 2012-02-01 2015-06-24 Abbvie Inc ONCE DAILY TREATMENT OF HEPATITIS C WITH RIBAVIRIN AND TARIBAVIRIN
EP3448392A4 (en) 2016-04-28 2020-01-15 Emory University ALKYNOUS THERAPEUTIC NUCLEOTIDE AND NUCLEOSIDE COMPOSITIONS AND RELATED APPLICATIONS

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4211771A (en) 1971-06-01 1980-07-08 Robins Ronald K Treatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide
USRE29835E (en) 1971-06-01 1978-11-14 Icn Pharmaceuticals 1,2,4-Triazole nucleosides
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US5676942A (en) * 1992-02-10 1997-10-14 Interferon Sciences, Inc. Composition containing human alpha interferon species proteins and method for use thereof

Also Published As

Publication number Publication date
US6299872B1 (en) 2001-10-09
PL323477A1 (en) 1998-03-30
AU5919296A (en) 1996-11-29
CA2221314A1 (en) 1996-11-21
NO975309L (no) 1997-11-19
EP1005868A1 (en) 2000-06-07
US6387365B1 (en) 2002-05-14
WO1996036351A1 (en) 1996-11-21
KR19990014925A (ko) 1999-02-25
NZ309217A (en) 2000-08-25
JPH10506640A (ja) 1998-06-30
CZ365497A3 (cs) 1998-07-15
EP0707855A2 (en) 1996-04-24
SK155997A3 (en) 1998-10-07
EP0707855A3 (en) 1996-11-27
CN1190895A (zh) 1998-08-19
HUP9802324A3 (en) 2001-04-28
MX9708885A (es) 1998-03-31
BR9608758A (pt) 1999-07-06
HUP9802324A2 (hu) 1999-05-28

Similar Documents

Publication Publication Date Title
NO975309D0 (no) Anvendelse av rivavirin og alfa-interferon til behandling av hepatitt C
FI950587L (fi) Endotoksiinimyrkytyksen ennaltaehkäisyssä ja hoidossa käyttökelpoisia menetelmiä
NO972236D0 (no) Dihydropyrimidiner og anvendelse derav
DK1174135T3 (da) Farmaceutisk sammensætning omfattende pioglitazon og glimepirid til anvendelse i behandling af diabetes
NO953991D0 (no) Ultrasomisk og elektro-kirurgisk håndstykke av piezotype
AU6588598A (en) Treatment of hepatitis b infection with thymosin alpha 1 and famciclovir
NO984094D0 (no) Utladningsreaktor og anvendelse av samme
DK0745396T3 (da) Blodpumpe og anvendelse deraf
DK0804078T3 (da) Sammensætning og anvendelse deraf
NO971900D0 (no) Blandinger og behandling av multippel sklerose
DK0898566T3 (da) Substituerede benzylaminer og anvendelse deraf til behandling af depression
FI933201L (fi) Vaerme- och kylvals
DK139393D0 (da) Laegetermometer med digitalt og talende display
NO982463D0 (no) Anvendelse av en kombinasjon av pentoksyfyllin og type I-interferoner til behandling av multippel sklerose
DK0548520T3 (da) Fremgangsmåde til fremstilling af 2-alkoxymethylacrolein og dets anvendelse til fremstilling af 3-alkoxymethylquinoliner
DE59306085D1 (de) Haar- und körperbehandlungsmittel
NO981719D0 (no) Anvendelse av protein S-100b i medisiner og medisiner inneholdende protein S-100b
FI933019L (fi) Bensotiazepin- och bensoxatzepinderivat
FI1031U1 (fi) En troakar
NO942686D0 (no) Anvendelse av 3-arylindol- og 3-arylindazolderivater ved behandling av psykoser
NO952194D0 (no) Spirofuranonderivater og deres anvendelse ved behandling av neurodegenerative sykdommer
KR940002718U (ko) 치질예방 및 치료기
DK55992D0 (da) Vaterpas med lyd og lys
KR940018880U (ko) 의자용 등받이와 팔꿈치 걸치게의 결착구조
DK117091D0 (da) Utraditionel tandpleje og paradentosebehandling

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application